C4 Therapeutics (CCCC) Revenue (2019 - 2026)

C4 Therapeutics' Revenue history runs 8 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• In Q1 2026, Revenue fell 15.0% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $34.9 million (down 12.37% YoY), while the FY2025 annual figure was $35.9 million, up 1.02% from the prior year.
• Revenue for Q1 2026 stood at $6.2 million, down from $11.0 million in the prior quarter.
• The five-year high for Revenue was $15.4 million in Q3 2024, with the low at $2.7 million in Q2 2023.
• The 5-year median for Revenue is $6.8 million (2022), against an average of $7.6 million.
• The sharpest annual moves came in 2022 and 2024: Revenue sank 85.79% in 2022, then soared 350.68% in 2024.
• C4 Therapeutics' Revenue stood at $2.9 million in 2022, then increased by 14.26% to $3.3 million in 2023, then surged by 58.75% to $5.2 million in 2024, then surged by 112.79% to $11.0 million in 2025, then slumped by 44.15% to $6.2 million in 2026.
• Business Quant data shows CCCC's Revenue at $6.2 million in Q1 2026, $11.0 million in Q4 2025, and $11.2 million in Q3 2025.